A novel candidate vaccine for cytauxzoonosis inferred from comparative apicomplexan genomics
- PMID: 23977000
- PMCID: PMC3748084
- DOI: 10.1371/journal.pone.0071233
A novel candidate vaccine for cytauxzoonosis inferred from comparative apicomplexan genomics
Erratum in
- PLoS One. 2013;8(10). doi:10.1371/annotation/943b121e-343b-4df1-a06b-7f8a205a057d
Abstract
Cytauxzoonosis is an emerging infectious disease of domestic cats (Felis catus) caused by the apicomplexan protozoan parasite Cytauxzoon felis. The growing epidemic, with its high morbidity and mortality points to the need for a protective vaccine against cytauxzoonosis. Unfortunately, the causative agent has yet to be cultured continuously in vitro, rendering traditional vaccine development approaches beyond reach. Here we report the use of comparative genomics to computationally and experimentally interpret the C. felis genome to identify a novel candidate vaccine antigen for cytauxzoonosis. As a starting point we sequenced, assembled, and annotated the C. felis genome and the proteins it encodes. Whole genome alignment revealed considerable conserved synteny with other apicomplexans. In particular, alignments with the bovine parasite Theileria parva revealed that a C. felis gene, cf76, is syntenic to p67 (the leading vaccine candidate for bovine theileriosis), despite a lack of significant sequence similarity. Recombinant subdomains of cf76 were challenged with survivor-cat antiserum and found to be highly seroreactive. Comparison of eleven geographically diverse samples from the south-central and southeastern USA demonstrated 91-100% amino acid sequence identity across cf76, including a high level of conservation in an immunogenic 226 amino acid (24 kDa) carboxyl terminal domain. Using in situ hybridization, transcription of cf76 was documented in the schizogenous stage of parasite replication, the life stage that is believed to be the most important for development of a protective immune response. Collectively, these data point to identification of the first potential vaccine candidate antigen for cytauxzoonosis. Further, our bioinformatic approach emphasizes the use of comparative genomics as an accelerated path to developing vaccines against experimentally intractable pathogens.
Conflict of interest statement
Figures
References
-
- Birkenheuer AJ, Le JA, Valenzisi AM, Tucker MD, Levy MG, et al. (2006) Cytauxzoon felis infection in cats in the mid-Atlantic states: 34 cases (1998–2004). J Am Vet Med Assoc 228: 568–571. - PubMed
-
- Cohn LA, Birkenheuer AJ, Brunker JD, Ratcliff ER, Craig AW (2011) Efficacy of atovaquone and azithromycin or imidocarb dipropionate in cats with acute cytauxzoonosis. J Vet Intern Med 25: 55–60. - PubMed
-
- Birkenheuer AJ, Marr H, Alleman AR, Levy MG, Breitschwerdt EB (2006) Development and evaluation of a PCR assay for the detection of Cytauxzoon felis DNA in feline blood samples. Vet Parasitol 137: 144–149. - PubMed
-
- Birkenheuer AJ, Marr HS, Warren C, Acton AE, Mucker EM, et al. (2008) Cytauxzoon felis infections are present in bobcats (Lynx rufus) in a region where cytauxzoonosis is not recognized in domestic cats. Vet Parasitol 153: 126–130. - PubMed
-
- Glenn BL, Stair EL (1984) Cytauxzoonosis in domestic cats: report of two cases in Oklahoma, with a review and discussion of the disease. J Am Vet Med Assoc 184: 822–825. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous
